






# Fluetizolam



Sample Type: Toxicology Sample

Latest Revision: December 8, 2022

Date Received: October 27, 2022

Date of Report: December 8, 2022

## **1. GENERAL INFORMATION**

| IUPAC Name:   | 4-ethyl-7-(2-fluorophenyl)-13-methyl-3-thia-1,8,11,12-<br>tetrazatricyclo[8.3.0.02,6]trideca-2(6),4,7,10,12-pentaene   |
|---------------|--|
| InChI String: | InChI=1S/C17H15FN4S/c1-3-11-8-13-16(12-6-4-5-7-<br>14(12)18)19-9-15-21-20-10(2)22(15)17(13)23-11/h4-8H,3,9H2,1-<br>2H3 |
| CFR:          | Not Scheduled (12/2022)  |
| CAS#          | 40054-88-4   |
| Synonyms:     | 2'-Fluorodeschloroetizolam   |
| Source:       | ACMT's Toxicology Investigators Consortium (ToxIC)   |

*Important Note*: All identifications were made based on evaluation of analytical data (LC-QTOF-MS) in comparison to analysis of acquired reference material.

**Prepared By:** Alex J. Krotulski, PhD; Alex Manini, MD; Jeff Brent, MD, PhD; Paul Wax, MD; Kim Aldy, MD; Sara E. Walton, MS; Melissa F. Fogarty, MSFS, D-ABFT-FT; and Barry K. Logan, PhD, F-ABFT

### 2. CHEMICAL AND PHYSICAL DATA

### 2.1 CHEMICAL DATA

| Drug        | Chemical            | Molecular | Molecular Ion     | Exact Mass         |
|-------------|---------------------|-----------|-------------------|--------------------|
|             | Formula             | Weight    | [M <sup>+</sup> ] | [M+H] <sup>+</sup> |
| Fluetizolam | $C_{17}H_{15}FN_4S$ | 326.4     | 326               | 327.1074           |

#### **3. SAMPLE HISTORY**

To date, Fluetizolam was identified in one clinical case since October 2022. The geographical and demographical breakdown is below:

| Geographical Location:    | Los Angeles (n=1)              |
|---------------------------|--------------------------------|
| <b>Biological Sample:</b> | Plasma (n=1)                   |
| Date of First Receipt:    | October 2022                   |
| Other Notable Findings:   | Pentylone, 3-OH-PCP, 4-MeO-PCP |

### **4. BRIEF DESCRIPTION**

Fluetizolam is classified as a novel benzodiazepine. Benzodiazepines are central nervous system depressants. Novel benzodiazepines, typically defined as emergent benzodiazepines not used medicinally, are often pirated from early drug discovery or pharmaceutical studies. Novel benzodiazepines have appeared on illicit drug markets in recent years and have caused adverse events, as described in the literature; fatalities linked to novel benzodiazepine use have occurred, commonly when used in combination with other depressants (e.g., opioids and alcohol). Fluetizolam is structurally similar to etizolam and other novel benzodiazepines. Fluetizolam is not federally controlled in the United States.

### **5. ADDITIONAL RESOURCES**


https://www.policija.si/apps/nfl\_response\_web/0\_Analytical\_Reports\_final/Fluetizolam-ID-3175-22\_report.pdf

https://www.caymanchem.com/product/36236/fluetizolam

# 6. QUALITATIVE DATA

### 6.1 GAS CHROMATOGRAPHY MASS SPECTROMETRY (GC-MS)

| Testing Performed At: | The Center for Forensic Science Research and Education at the Fredric Rieders Family Foundation (Willow Grove, PA)  |
|-----------------------|---|
| Sample Preparation:   | Standard diluted in methanol  |
| Instrument:           | Agilent 5975 Series GC/MSD System   |
| Standard:             | Reference material for fluetizolam (Batch: 0637445-2) was<br>purchased from Cayman Chemical Company (Ann Arbor, MI,<br>USA). (https://www.caymanchem.com/product/36236/fluetizolam) |





### EI (70 eV) Mass Spectrum: Fluetizolam (Standard)


# 6.2 LIQUID CHROMATOGRAPHY QUADRUPOLE TIME-OF-FLIGHT MASS SPECTROMETRY (LC-QTOF-MS)

| Testing Performed At:        | The Center for Forensic Science Research and Education at the Fredric Rieders Family Foundation (Willow Grove, PA)  |  |
|------------------------------|---|--|
| Sample Preparation:          | Liquid-liquid extraction (LLE)  |  |
| Instrument:                  | Sciex X500R, Sciex ExionLC  |  |
| Column:                      | Phenomenex® Kinetex C18 (50 mm x 3.0 mm, 2.6 µm)  |  |
| Mobile Phase:                | A: Ammonium formate (10 mM, pH 3.0)   |  |
|                              | B: Methanol/acetonitrile (50:50)  |  |
|                              | Flow rate: 0.4 mL/min   |  |
| Gradient:                    | Initial: 95A:5B; 5A:95B over 13 min; 95A:5B at 15.5 min   |  |
| Temperatures:                | Autosampler: 15 °C  |  |
|                              | Column Oven: 30 °C  |  |
|                              | Source Heater: 600 °C   |  |
| <b>Injection Parameters:</b> | Injection Volume: 10 µL   |  |
| <b>QTOF Parameters:</b>      | TOF MS Scan Range: 100-510 Da   |  |
|                              | Precursor Isolation: SWATH® acquisition (27 windows)  |  |
|                              | Fragmentation: Collison Energy Spread (35±15 eV)  |  |
|                              | MS/MS Scan Range: 50-510 Da   |  |
| <b>Retention Time:</b>       | 7.43 min  |  |
| Standard Comparison:         | Reference material for fluetizolam (Batch: 0637445-2) was<br>purchased from Cayman Chemical Company (Ann Arbor, MI,<br>USA). Analysis of this standard resulted in positive identification<br>of the analyte in the extract as fluetizolam, based on retention time<br>(7.47 min) and mass spectral data.<br>(https://www.caymanchem.com/product/36236/fluetizolam) |  |


# **Extracted Ion Chromatogram: Fluetizolam**







#### **MS/MS Spectra: Fluetizolam**



#### 7. FUNDING

Funding for sample collection and analysis was received from the National Institute on Drug Abuse (NIDA) from the National Institutes of Health (NIH), Award Number: R01DA048009. The opinions, findings, conclusions and/or recommendations expressed in this publication are those of the authors and do not necessarily reflect those of the NIH.

NPS Discovery at the CFSRE is supported in part by the National Institute of Justice, Office of Justice Programs, U.S. Department of Justice (Award Number 2020-DQ-BX-0007, "Real-Time Sample-Mining and Data-Mining Approaches for the Discovery of Novel Psychoactive Substances (NPS)"). The opinions, findings, conclusions and/or recommendations expressed in this publication are those of the author(s) and do not necessarily represent the official position or policies of the U.S. Department of Justice.